Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isatuximab + Chemotherapy in Pediatric Relapsed/Refractory ALL or AML
NCT03860844Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Aug 2019
- Primary completion
- Sep 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 16
01
Overview
Phase 2, open-label, single-arm trial of isatuximab in acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), sponsored by Sanofi. Primary endpoint: Percentage of Participants With Complete Response Rate. Started Aug 2019; status: terminated.
02
Drugs
isatuximab
03
Conditions
acute lymphoblastic leukemia (ALL)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03860844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03860844.